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ORIGINAL ARTICLEMolecular survey of aminoglycoside-resistant Acinetobacter baumannii
isolated from tertiary hospitals in Qazvin, IranP. Rashvand1, A. Peymani2, M. Mohammadi1, A. A. Karami3, R. Samimi2, S. Hajian4, D. Porasgari2 and N. Habibollah-Pourzereshki2
1) Student Research Committee, 2) Medical Microbiology Research Centre, 3) Department of Urology, School of Medicine and 4) Department of Nephrology,
Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, IranAbstractAminoglycoside-modifying enzymes (AMEs) and 16S rRNA methylases (16S RMTase) are two main resistance mechanisms against
aminoglycosides. This study aimed to evaluate the frequency of AMEs and 16S rRNA methylase genes among aminoglycoside non-
susceptible Acinetobacter baumannii isolates and to assess their clonal relationship using repetitive extragenic palindromic-PCR (rep-PCR).
In this cross-sectional study, a total of 192 A. baumannii isolates were collected from the patients hospitalized in Qazvin, Iran (January
2016 to January 2018). Identification of isolates was performed by standard laboratory methods and API 20E strips. Antimicrobial
susceptibility was determined by Kirby–Bauer method followed by examination of the genes encoding the AMEs and 16S RMTase by
PCR and sequencing methods. The clonal relationship of isolates was carried out by rep-PCR. In total, 98.4% of isolates were non-
susceptible to aminoglycosides, 98.4%, 97.9% and 83.9% of isolates were found to be non-susceptible against gentamicin, tobramycin and
amikacin, respectively. The frequencies of aph(30)-VI, aac(60)-Ib, aac(3)-II, aph(30)-Ia and armA genes were 59.3%, 39.2%, 39.2%, 31.7% and
69.8%, respectively, either alone or in combination. Rep-PCR results showed that the aminoglycoside non-susceptible isolates belonged to
three distinct clones: A (79.4%), B (17.5%) and C (3.2%). The findings of this study showed a high frequency for AMEs with the
emergence of armA genes among the aminoglycoside non-susceptible A. baumannii isolates. Rational administration of aminoglycosides as
well as using an appropriate infection control policy may reduce the presence of resistance to antibiotics in medical centres.
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E-mail: a.peymani@gmail.comIntroductionAcinetobacter baumannii is a clinically important Gram-negative
pathogen in medical centres. This bacterium is responsible for
various types of nosocomial infections including pneumonia,
bacteraemia, surgical site infections, and urinary tract infections
[1]. In recent years, the emergence of multidrug resistance to
antibiotics has become a major clinical concern for physicians.This is an open access artiThis problem leads to serious limitations in the treatment of
patients infected with these pathogens, and to increased
morbidity and mortality [2,3]. Aminoglycosides are the most
frequently used antibiotic agents among topically applied anti-
biotics in the treatment of infections caused by Gram-negative
bacteria. Combining an aminoglycoside with a β-lactam is
considered to be more effective treatment againstinfections
caused by Gram-negative bacteria [4]. These antibiotics block
protein synthesis in the bacterium by binding to 30S ribosome
and eventually lead to bacterial death [5]. Indiscriminate use of
these antibiotics increases antibiotic resistance in bacteria and
makes the therapy ineffective [6]. Resistance to aminoglycosides
may occur based on the following mechanisms: (a) drug inac-
tivation using aminoglycoside-modifying enzymes (AMEs), (b)
ribosomal binding site alterations, (c) reduction of antibiotic
enzyme regulation by down-regulation of porin genes; and (d)New Microbe and New Infect 2021; 42: 100883
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